- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.03. | Novartis shares positive phase 3 results for spinal muscular atrophy gene therapy | ||
| 20.03. | Harnessing AI and big data in clinical research | ||
| 19.03. | Pfizer/Arvinas' vepdegestrant shows promise in phase 3 breast cancer study | ||
| 19.03. | AbbVie's Elahere shows consistent survival benefits in late-stage ovarian cancer trial | ||
| 19.03. | Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients | ||
| 19.03. | Breaking down the barriers | ||
| 18.03. | Boehringer Ingelheim and Salipro Biotech enter drug development partnership | ||
| 18.03. | AstraZeneca to expand cell therapy capabilities with $1bn EsoBiotec acquisition | ||
| 18.03. | NICE recommends Pharming's Joenja as first treatment for ultra-rare immune disease APDS | ||
| 17.03. | Bristol Myers Squibb granted EC approval for Breyanzi in follicular lymphoma | ||
| 17.03. | Roche to launch new innovation centre at Harvard's Enterprise Research Campus | ||
| 17.03. | Amgen's Uplizna shows promise in phase 3 generalised myasthenia gravis study | ||
| 17.03. | 2025 PM Society Awards - winners announced | ||
| 14.03. | AstraZeneca/Ionis' Wainzua granted EC approval to treat rare disease ATTRv-PN | ||
| 14.03. | DSRU appoints Linda Härmark as director | ||
| 14.03. | Prime minister unveils UK government's plans to abolish NHS England | ||
| 13.03. | World Kidney Day - Boehringer launches CKD initiative to tackle UK health inequalities | ||
| 13.03. | Biogen initiates phase 3 study of felzartamab in kidney transplant patients | ||
| 13.03. | NICE recommends Gideon Richter's Ryeqo as first daily pill for endometriosis | ||
| 12.03. | Roche and Zealand Pharma partner on mid-stage obesity candidate in deal worth $5.3bn | ||
| 12.03. | Merck KGaA's Mavenclad tablets recommended by NICE for wider MS use | ||
| 12.03. | Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis | ||
| 11.03. | Novartis gains rights to Kyorin's chronic spontaneous urticaria candidate in deal worth $830m | ||
| 11.03. | Vertex's triple combination cystic fibrosis therapy Alyftrek approved by MHRA | ||
| 11.03. | J&J/Protagonist's icotrokinra shows promise in phase 3 plaque psoriasis programme |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
